SCORR featured in International CRO Publication

SCORR Marketing Case Study Recognized in International CRO Publication

SCORR Marketing has been recognized in the September issue of the international pharmaceutical intelligence magazine, Pharmafocus, in a case study for their client, DaVita Clinical Research (DCR).

SCORR Marketing conducted primary research with company stakeholders and customers to identify their perception of DCR’s strengths and weaknesses, as well as the marketing opportunities and threats proposed for DCR. A Strategic Marketing Action Plan (Strat MAP) was then prepared. This document guided the creative team in aligning the marketing strategy with the creative elements to clearly delineate the DCR advantage to pharmaceutical and biotech companies.

SCORR Marketing is a full-service marketing and public relations firm offering complete strategic communications programs to clients in a wide variety of markets and industries. For more information or to view samples of their work, visit online at or call 308.237.5567.

About SCORR Marketing
SCORR collaborates with energetic companies to develop “next-phase growth strategies” and a disciplined approach to marketing plans that ensure solid incremental growth year after year, creating tangible results. SCORR’s team includes dedicated talent with worldwide experience in market development, public relations and communications, customer retention and development, corporate identity/branding, broadcast and print advertising, and interactive/Web design and development, as well as tradeshow/event planning and promotion. Connect with SCORR Marketing on Facebook, LinkedIn and Twitter, or call us at 308.237.5567.

About Pharmafocus
Pharmafocus is a newspaper-style publication that provides high-quality pharmaceutical intelligence for the UK and European markets. Pharmafocus is also supported by news alerts, which provide exclusive news and analysis from the industry. Circulated monthly to 9,000 executives with both UK and European responsibility, Pharmafocus content covers all areas of the drug lifecycle, with strong focus on phases II to IV.